Analytical Data
-
基因名
CHRNb4
- Application
-
别名
CHRNb4；Neuronal acetylcholine receptor subunit beta-4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P30926
-
表达区间
1-498aa
-
氨基酸序列
MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRD
-
分子量
56.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CHRnB4 protein, a subtype of nicotinic acetylcholine receptors (nAChRs), has garnered significant interest in neuroscientific research due to its critical role in modulating neurotransmission in the central and peripheral nervous systems. This receptor subtype is predominantly expressed in the brain, where it influences various cognitive functions, including learning, memory, and attention. Furthermore, CHRnB4 has been implicated in a range of neurological disorders, such as Alzheimer's disease, schizophrenia, and nicotine addiction. Researchers are investigating the structure and functional dynamics of recombinant CHRnB4 proteins to better understand their molecular mechanisms and potential therapeutic targets. Advanced techniques, including X-ray crystallography and electrophysiological assays, are employed to characterize the receptor’s binding sites and activation pathways. By elucidating the pharmacological properties of CHRnB4, scientists aim to develop novel compounds that can selectively modulate its activity, thus paving the way for innovative treatments for diseases associated with cholinergic dysfunction. As the understanding of CHRnB4 continues to evolve, its potential as a biomarker for neurological conditions and a target for drug discovery remains an area of active exploration.
